O
11.52
0.55 (5.01%)
| Previous Close | 10.97 |
| Open | 10.97 |
| Volume | 3,714,769 |
| Avg. Volume (3M) | 2,585,906 |
| Market Cap | 2,441,136,896 |
| Price / Sales | 33.05 |
| Price / Book | 7.66 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -597.47% |
| Diluted EPS (TTM) | -1.11 |
| Quarterly Revenue Growth (YOY) | -27.60% |
| Total Debt/Equity (MRQ) | 28.66% |
| Current Ratio (MRQ) | 10.22 |
| Operating Cash Flow (TTM) | -145.46 M |
| Levered Free Cash Flow (TTM) | -87.96 M |
| Return on Assets (TTM) | -27.21% |
| Return on Equity (TTM) | -57.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ocular Therapeutix, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.6
| Analyst Consensus | 5.0 |
| Insider Activity | -4.0 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.60 |
|
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.82% |
| % Held by Institutions | 87.01% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Summer Road Llc | 30 Jun 2025 | 13,887,468 |
| Deltec Asset Management Llc | 30 Jun 2025 | 2,794,892 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 31.00 (Piper Sandler, 169.10%) | Buy |
| Median | 21.00 (82.29%) | |
| Low | 19.00 (HC Wainwright & Co., 64.93%) | Buy |
| Average | 23.43 (103.39%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 11.48 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Oct 2025 | 19.00 (64.93%) | Buy | 11.91 |
| Baird | 03 Oct 2025 | 24.00 (108.33%) | Buy | 11.41 |
| Piper Sandler | 03 Oct 2025 | 31.00 (169.10%) | Buy | 11.41 |
| Chardan Capital | 02 Oct 2025 | 21.00 (82.29%) | Buy | 11.06 |
| 15 Sep 2025 | 21.00 (82.29%) | Buy | 12.54 | |
| JMP Securities | 01 Oct 2025 | 29.00 (151.74%) | Buy | 11.04 |
| Needham | 01 Oct 2025 | 20.00 (73.61%) | Buy | 11.04 |
| 05 Aug 2025 | 15.00 (30.21%) | Buy | 12.00 | |
| Scotiabank | 06 Aug 2025 | 20.00 (73.61%) | Buy | 12.50 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ANDERMAN TODD | - | 11.91 | -11,132 | -132,582 |
| HEIER JEFFREY S. | - | 11.06 | -10,502 | -116,152 |
| KAISER PETER | - | 11.06 | -9,653 | -106,762 |
| Aggregate Net Quantity | -31,287 | |||
| Aggregate Net Value ($) | -355,496 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 11.34 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ANDERMAN TODD | Officer | 08 Oct 2025 | Sell (-) | 11,132 | 11.91 | 132,582 |
| HEIER JEFFREY S. | Officer | 02 Oct 2025 | Sell (-) | 10,502 | 11.06 | 116,152 |
| KAISER PETER | Officer | 02 Oct 2025 | Sell (-) | 9,653 | 11.06 | 106,762 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |